

09.06.2023

## **News Release**

**BIOMANEO** 

22B Bd Winston Churchill 21000 DIJON - France

contact@biomaneo.com +33 (0)3 74 95 08 40 www.biomaneo.com

## International development of Biomaneo

Biomaneo becomes a subsidiary of Shimadzu Corporation

The founders of Biomaneo (Dijon, France), Patrick Ducoroy and Valérie Geoffroy, are pleased to announce that, on 31 May 2023, Biomaneo, specialized in software and kit reagents for clinical applications, became a wholly-owned subsidiary of Shimadzu Corporation (Kyoto, Japan). Shimadzu Corporation is a Japanese company, well established internationally, with a high level specialization in the manufacture of medical analysis equipments. This acquisition is the result of a shared willingness to combine the synergies and skills of the two companies in the clinical field.

Indeed, the collaboration between Biomaneo and the Shimadzu group has been initiated in 2018 with Shimadzu Europa GmbH (SEG) and Kratos (UK), subsidiaries of Shimadzu Corporation, through the development of new medical devices using the Shimadzu technology and the distribution of software for newborn screening tests (NBS). Today, with the increasing use of liquid chromatography mass spectrometers (LCMS) in clinical chemistry applications (mainly blood tests), the needs and changes in hospital information systems (Laboratory Information System, LIS) and the changes in IVDD regulations, Shimadzu is acquiring Biomaneo's expertise to develop complete clinical solutions combining analytical equipment, LIS and software (automatic link between equipment data and LIS), in compliance with the new European regulation 2017/746 (IVDR).

Biomaneo is ISO 13485 certified and markets DMDIV analysis solutions for screening haemoglobinopathies by mass spectrometry as well as software dedicated to the screening/diagnosis of pathologies with other analysis instrumentations to improve traceability, quality monitoring, biological interpretation of data and medical reporting. With Shimadzu's commercial support and instrumental expertise, the Biomaneo concept will be able to develop internationally and extend for various tests and new global solutions using LCMS, CLAM-2040 fully automated LCMS pre-treatment equipment, MALDI-8020 matrix-assisted laser desorption/ionization time-of-flight mass spectrometer, as well as reagents from Alsachim (subsidiary of Shimadzu specialized in TDM) and Shimadzu Diagnostics.

Details of Biomaneo:

Company Name: Biomaneo, SAS President: Kunihiko Koriyama

Address: 22B Boulevard Winston Churchill 21000 Dijon-France

Capital: 60,909EUR Number of employees: 8 Founded: May 9, 2016 Website: https://biomaneo.fr/en/

Shimadzu Corporation Website: https://www.shimadzu.co.jp